目次

CONTENTS

1 Executive Summary

2 Global Biological Therapies for Cancer Market
2.1. Product Overview
2.2. Market Definition
2.3. Segmentation
2.4. Assumptions and Acronyms

3 Research Methodology
3.1. Research Objectives
3.2. Primary Research
3.3. Secondary Research
3.4. Forecast Model
3.5. Market Size Estimation

4 Average Pricing Analysis

5 Macro-Economic Indicators

6 Market Dynamics
6.1. Growth Drivers
6.2. Restraints
6.3. Opportunity
6.4. Trends

7 Correlation & Regression Analysis
7.1. Correlation Matrix
7.2. Regression Matrix

8 Recent Development, Policies & Regulatory Landscape

9 Risk Analysis
9.1. Demand Risk Analysis
9.2. Supply Risk Analysis

10 Global Biological Therapies for Cancer Market Analysis
10.1. Porters Five Forces
10.1.1. Threat of New Entrants
10.1.2. Bargaining Power of Suppliers
10.1.3. Threat of Substitutes
10.1.4. Rivalry
10.2. PEST Analysis
10.2.1. Political
10.2.2. Economic
10.2.3. Social
10.2.4. Technological

11 Global Biological Therapies for Cancer Market
11.1. Market Size & forecast, 2020A-2030F
11.1.1. By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
11.1.2. By Volume (Million Units) 2020-2030F; Y-o-Y Growth (%) 2021-2030F

12 Global Biological Therapies for Cancer Market: Market Segmentation
12.1. By Regions
12.1.1. North America:(U.S. and Canada), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.2. Latin America: (Brazil, Mexico, Argentina, Rest of Latin America), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.3. Europe: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F

12.1.5. Middle East and Africa: (Israel, GCC, North Africa, South Africa, Rest of Middle East and Africa), By Value (USD Million) 2020-2030F; Y-o-YGrowth (%) 2021-2030F
12.2. By Type:Market Share (2020-2030F)
12.2.1. Monoclonal antibodies, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.2. Vaccines, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.3. Cancer growth blockers, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.4. Blood cell growth factors, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.5. Cytokines, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3. By Application: Market Share (2020-2030F)
12.3.1. Specialized cancer treatment centers, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.2. Hospitals Pharmacies, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.3. Retail Pharmacies, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F

13 Company Profile
13.1. Bayer AG
13.1.1. Company Overview
13.1.2. Company Total Revenue (Financials)
13.1.3. Market Potential
13.1.4. Global Presence
13.1.5. Key Performance Indicators
13.1.6. SWOT Analysis
13.1.7. Product Launch
13.2. Amgen Inc.
13.3. Celgene Corporation
13.4. Eisai Co., Ltd.
13.5. Hikma Pharmaceuticals PLC
13.6. Incyte Corp
13.7. Johnson & Johnson Services, Inc
13.8. Otsuka Pharmaceutical Co., Ltd
13.9. Pfizer, Inc
13.10. Other Prominent Players

14 Consultant Recommendation
**The above given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.